Created On: 2020-07-15
Record Count: 6
- Scientific & Technical Instruments
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26420
The license granted includes the right of LICENSEE to grant Sublicense to third parties during the Term.
The License technology relates to oxygen delivery devices that incorporate a computer controlled, patient-adaptive dosing system, for people who use supplemental oxygen therapy.
SOSâ€™s Intended Products
The full function products that SOS plans to develop include stationary and mobile versions of a supplemental oxygen delivery control device that uses, for each breath, blood oxygen readings and inhaled breath depth measurements to deliver an appropriate oxygen flow to satisfy the userâ€™s need. As a user requires a greater volume of oxygen, the SOS device would be designed to automatically respond, breath by breath, to deliver the appropriate oxygen dose. Blood oxygen readings would be taken by an integrated pulse oximeter (a non-invasive monitoring device) attached to the userâ€™s finger or ear. Inhaled breath depth measurements would be taken from the air hose that delivers the oxygen to the user. Unlike continuous-flow supplemental oxygen delivery devices, the planned SOS device would not deliver oxygen flow while the user is exhaling, and thus may serve an oxygen conserving function as well.
'Patent Rights' means UNIVERSITY's rights in any of the following: the US patent application (serial number 13/814,934 titled 'Automated Fluid Delivery System and Method').
The Licensee will try to develop a supplemental oxygen delivery device that would incorporate a computer controlled, patient-adaptive dosing system for use by people who require supplemental oxygen therapy. The device is may be used by people who have been prescribed supplemental oxygen by their doctor. It is being developed to deliver the benefit of an oxygen conserving device and the benefit of delivering a dose of oxygen commensurate with demand.
IPSCIO Record ID: 1153
IPSCIO Record ID: 27802
IPSCIO Record ID: 6696
US Patent# 7,407,632 entitled Apparatus and delivery of medically pure oxygen;
US Patent# 7,381,377 entitled Method for controlled production of a gas;
US Patent# 7,465,428 entitled Method and apparatus for controlled production of a gas;
US Patent# D549,341 entitled Breathing device utilizing a catalytic oxygen generation method;
US Patent# D549,342 entitled Breathing device utilizing a catalytic oxygen generation method;
US Patent# D/320,358 entitled Chemical reaction activation plunger;
South African Patent # 2006/5051 entitled Method and apparatus for generating oxygen.
IPSCIO Record ID: 28235
INOpulse is based on the Companyâ€™s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.
The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patientâ€™s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patientâ€™s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.
IPSCIO Record ID: 3240
The Licensor also granted the Licensee a non-exclusive, perpetual and worldwide license, with sublicense rights, to use Masimo SETÂ® for the measurement of vital signs in the Licensee Market.
Pursuant to the Cross-Licensing Agreement, the Licensor has licensed from the Licensee the right to make and distribute products in the Licensor Market that utilize rainbowÂ® technology for the measurement of only carbon monoxide, methemoglobin, fractional arterial oxygen saturation and hemoglobin, which includes hematocrit
RainbowÂ® SET platform utilizing both Masimo SETÂ® and licensed rainbowÂ® technology, includes devices cleared by the U.S. Food and Drug Administration, to noninvasively and continuously monitor multiple measurements that previously required invasive or complicated procedures.